Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + SOC in Advanced HCC
NCT06301399Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate at 12 months. Started Mar 2024; status: recruiting.
02
Drugs
rituximab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06301399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06301399.